BioGaia appoints Theresa Agnew as new CEO

Today BioGaia´s board of directors has appointed Theresa P. Agnew as the new chief executive officer.

Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College.

At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide.

Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale.

"We are extremely pleased that we have been able to recruit Theresa Agnew”, says BioGaia’s founder and chair Peter Rothschild, and he continues: “She has successfully led OTC, diagnostics, and consumer health brands with a strong scientific basis and been a pioneer expanding distribution through internet platforms. She brings experience from turnaround environments as well as growth-oriented roles. Theresa has a deep knowledge of life science, as well as how to build and market strong and relevant consumer brands. Theresa will drive BioGaia to further accelerate its profitable growth journey and potential.”

"I am very excited about this opportunity and really look forward to contributing to an already successful business model and working with the talented global BioGaia team to grow BioGaia and create value for our consumers and shareholders”, says Theresa Agnew, future CEO of BioGaia.

Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Peter Rothschild, Chairman of the Board
Email: [email protected]
Phone: +46 708 30 65 40

About BioGaia
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm.

This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 3:30 p.m. CEST on August 2, 2023.